Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ranson

Showing results (101-110 of 158) with videos related to

Pageof 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding studyM Ranson, M Reck, A Anthoney, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
MMAF for advanced gastric cancerH Anderson, J H Scarffe, M Ranson, et al.
Scientific Reports|June 22, 2021
Interaction between genetic predisposition, smoking, and dementia risk: a population-based cohort studyNa Zhang, Janice M Ranson, Zhi-Jie Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1990
Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinomaH Gurney, D Crowther, H Anderson, et al.
International Journal of Cancer|September 29, 2000
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targetsJ L Yang, D q Seetoo, Y Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cyclesD Murphy, D Crowther, J Renninson, et al.
Bone Marrow Transplantation|June 1, 1994
Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresisM E Van Hoef, M Ranson, G R Morgenstern, et al.
Annals of Vascular Surgery|August 21, 2007
Regional nerve block allows for optimization of planning in the creation of arteriovenous access for hemodialysis by improving superficial venous dilatationI A Laskowski, B Muhs, C R Rockman, et al.
The HUGO Journal|December 2, 2011
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumoursK L Aung, R E Board, G Ellison, et al.
Pageof 16

Showing results (101-110 of 158) with videos related to

Sort By:
Pageof 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding studyM Ranson, M Reck, A Anthoney, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
MMAF for advanced gastric cancerH Anderson, J H Scarffe, M Ranson, et al.
Scientific Reports|June 22, 2021
Interaction between genetic predisposition, smoking, and dementia risk: a population-based cohort studyNa Zhang, Janice M Ranson, Zhi-Jie Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1990
Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinomaH Gurney, D Crowther, H Anderson, et al.
International Journal of Cancer|September 29, 2000
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targetsJ L Yang, D q Seetoo, Y Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cyclesD Murphy, D Crowther, J Renninson, et al.
Bone Marrow Transplantation|June 1, 1994
Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresisM E Van Hoef, M Ranson, G R Morgenstern, et al.
Annals of Vascular Surgery|August 21, 2007
Regional nerve block allows for optimization of planning in the creation of arteriovenous access for hemodialysis by improving superficial venous dilatationI A Laskowski, B Muhs, C R Rockman, et al.
The HUGO Journal|December 2, 2011
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumoursK L Aung, R E Board, G Ellison, et al.
Pageof 16